BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 22605458)

  • 1. Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target.
    Ginestier C; Monville F; Wicinski J; Cabaud O; Cervera N; Josselin E; Finetti P; Guille A; Larderet G; Viens P; Sebti S; Bertucci F; Birnbaum D; Charafe-Jauffret E
    Stem Cells; 2012 Jul; 30(7):1327-37. PubMed ID: 22605458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
    Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
    Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mevalonate precursor enzyme HMGCS1 is a novel marker and key mediator of cancer stem cell enrichment in luminal and basal models of breast cancer.
    Walsh CA; Akrap N; Garre E; Magnusson Y; Harrison H; Andersson D; Jonasson E; Rafnsdottir S; Choudhry H; Buffa F; Ragoussis J; Ståhlberg A; Harris A; Landberg G
    PLoS One; 2020; 15(7):e0236187. PubMed ID: 32692762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
    Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
    J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Wnt1 expression reduces the enrichment of cancer stem cells in a mouse model of breast cancer.
    Choi AR; Park JR; Kim RJ; Kim SR; Cho SD; Jung JY; Nam JS
    Biochem Biophys Res Commun; 2012 Aug; 425(2):436-42. PubMed ID: 22846569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into the cell of origin in breast cancer and breast cancer stem cells.
    Lindeman GJ; Visvader JE
    Asia Pac J Clin Oncol; 2010 Jun; 6(2):89-97. PubMed ID: 20565420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.
    Cirenajwis H; Smiljanic S; Honeth G; Hegardt C; Marton LJ; Oredsson SM
    Anticancer Drugs; 2010 Nov; 21(10):897-906. PubMed ID: 20838207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Wnt/β-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer.
    Cai C; Zhu X
    Mol Med Rep; 2012 May; 5(5):1191-6. PubMed ID: 22367735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo antiproliferative activity of metformin on stem-like cells isolated from spontaneous canine mammary carcinomas: translational implications for human tumors.
    Barbieri F; Thellung S; Ratto A; Carra E; Marini V; Fucile C; Bajetto A; Pattarozzi A; Würth R; Gatti M; Campanella C; Vito G; Mattioli F; Pagano A; Daga A; Ferrari A; Florio T
    BMC Cancer; 2015 Apr; 15():228. PubMed ID: 25884842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliminating drug resistant breast cancer stem-like cells with combination of simvastatin and gamma-tocotrienol.
    Gopalan A; Yu W; Sanders BG; Kline K
    Cancer Lett; 2013 Jan; 328(2):285-96. PubMed ID: 23063651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The in vitro and in vivo effects of human umbilical cord mesenchymal stem cells on the growth of breast cancer cells.
    Ma Y; Hao X; Zhang S; Zhang J
    Breast Cancer Res Treat; 2012 Jun; 133(2):473-85. PubMed ID: 21947651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.
    Charafe-Jauffret E; Ginestier C; Bertucci F; Cabaud O; Wicinski J; Finetti P; Josselin E; Adelaide J; Nguyen TT; Monville F; Jacquemier J; Thomassin-Piana J; Pinna G; Jalaguier A; Lambaudie E; Houvenaeghel G; Xerri L; Harel-Bellan A; Chaffanet M; Viens P; Birnbaum D
    Cancer Res; 2013 Dec; 73(24):7290-300. PubMed ID: 24142344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-κB activation and tumor sphere formation.
    Glinka Y; Mohammed N; Subramaniam V; Jothy S; Prud'homme GJ
    Biochem Biophys Res Commun; 2012 Sep; 425(4):775-80. PubMed ID: 22885184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis.
    Marcato P; Dean CA; Pan D; Araslanova R; Gillis M; Joshi M; Helyer L; Pan L; Leidal A; Gujar S; Giacomantonio CA; Lee PW
    Stem Cells; 2011 Jan; 29(1):32-45. PubMed ID: 21280157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer.
    Kondratyev M; Kreso A; Hallett RM; Girgis-Gabardo A; Barcelon ME; Ilieva D; Ware C; Majumder PK; Hassell JA
    Oncogene; 2012 Jan; 31(1):93-103. PubMed ID: 21666715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
    Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ
    Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination.
    Fonseca NA; Rodrigues AS; Rodrigues-Santos P; Alves V; Gregório AC; Valério-Fernandes Â; Gomes-da-Silva LC; Rosa MS; Moura V; Ramalho-Santos J; Simões S; Moreira JN
    Biomaterials; 2015 Nov; 69():76-88. PubMed ID: 26283155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.